FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer (Q33508936)

27 July 2017

title

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer (English)

1 reference

27 July 2017

main subject

phase III clinical trial

0 references

1 reference

Simon I Noble

3

0 references

Gareth O Griffiths

object named as

Gareth O Griffiths

1

1 reference

ORCID Public Data File 2021

author name string

Sarah Burns

2

1 reference

27 July 2017

Fergus R Macbeth

4

1 reference

27 July 2017

David Cohen

5

1 reference

27 July 2017

Timothy S Maughan

6

1 reference

27 July 2017

language of work or name

English

0 references

publication date

6 October 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

9

1 reference

27 July 2017

page(s)

355

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

copyright license

start time

6 October 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Venous thromboembolism and cancer: risks and outcomes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

The low molecular weight heparin, tinzaparin, in thrombosis and beyond.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Anticoagulants in thrombosis and cancer: the missing link

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Cancer and blood coagulation: molecular aspects.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Antithrombotic therapy in cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Pathophysiology of the thrombophilic state in the cancer patient

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Laboratory diagnosis of the thrombophilic state in cancer patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Venous thromboembolism and cancer.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Deep vein thrombosis of the leg. Is there a "high risk" group?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Modulation of neovascularization and metastasis by species of heparin

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Epidemiology of Lung Cancer*

14 July 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2761945

Prognosis of Cancers Associated with Venous Thromboembolism

31 October 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-9-355

Haemostatic abnormalities in lung cancer: prognostic implications

21 January 2018

1 reference

12 December 2020

Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE

1 reference

12 December 2020

Inhibition of metastases by anticoagulants

1 reference

12 December 2020

The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer

1 reference

12 December 2020

Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice

1 reference

12 December 2020

Perioperative heparin-therapy inhibits late death from metastatic cancer

1 reference

12 December 2020

1 reference

12 December 2020

The epidemiology of lung cancer

1 reference

12 December 2020

Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic impact of an activation of coagulation in lung cancer

1 reference

12 December 2020

Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis

1 reference

12 December 2020

Angiogenesis: a dynamic balance of stimulators and inhibitors

1 reference

12 December 2020

Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-9-355

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference